A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

A Pilot, Randomized, Open-label Study in Patients on Chronic Dialysis With End Stage Renal Disease (Esrd), to Evaluate the Enhancing Effect of Two Doses of Thymosin Alpha 1 on the Immunogenicity of h1n1sw Monovalent Vaccine

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01031966

Enrollment

120

Registered

2009-12-15

Start date

2009-11-30

Completion date

2010-07-31

Last updated

2012-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

END STAGE RENAL DISEASE

Keywords

ESRD

Brief summary

The purpose of this explorative trial is to collect preliminary data on efficacy and safety of thymosin alpha 1 given at different doses as an adjuvant to egg-derived H1N1sw monovalent influenza vaccine in hemodialysis patients. The final aim is that of gathering information needed for planning a following confirmatory study on the efficacy and safety of Thymosin alpha 1 in the same indication.

Detailed description

The emergence and spread of the novel influenza A (H1N1) virus has been of great concern globally. Uremic patients are especially vulnerable to infections and it is generally recommended to vaccinate patients with chronic renal insufficiency yearly against influenza. In patients on haemodialysis (HD) the vaccination response has been considered suboptimal. Decreased antibody response to T-cell dependent antigens may be one factor that accounts for insufficient efficacy of certain vaccination programs (eg, influenza). Diminished antibody responses have also been reported in patients with end-stage renal disease. The evidence for impairment of cell-mediated immunity in hemodialysis patients has been attributed to incompetence in T-cell-mediated immune responses. Since Zadaxin can enhance T-cell-dependent specific antibody production, the addition of Zadaxin (Thymosin alpha 1)to vaccination programs for immunocompromised individuals should be effective.

Interventions

BIOLOGICALMF59 adjuvanted H1N1 influenza monovalent vaccine

One/two single administration

DRUGThymosin alpha 1

1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Signed written informed consent. 2. Age \> 18 . 3. Chronic dialysis for ESRD . 4. Life expectancy of at least 6 months.

Exclusion criteria

1. They have any serious disease 2. They are hypersensitive to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine. 3. They have a history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine. 4. Within the past 3 days, they have experienced fever (i.e., axillary temperature \_ 38°C). 5. They have any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.

Design outcomes

Primary

Measure	Time frame
The measures of immunogenicity, as determined by HI; MN and SRH	Geometric mean HI titer (GMT) on Day 0, Day 21, Day 42, Day 84 and Day 168 for the primary course

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026